Amylyx Pharmaceuticals (AMLX)

Executive Summary

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a biopharmaceutical company focused on neurodegenerative diseases. Its only approved product, RELYVRIO (AMX0035) for ALS, faced a major setback in November 2024 when the Phase 3 PHOENIX trial failed to meet its primary endpoint, leading to a voluntary withdrawal from the market. The company has since restructured, reducing its workforce and pivoting to a pipeline of earlier-stage assets. Key programs include AMX0035 in Wolfram Syndrome (Phase 2) and progressive supranuclear palsy (Phase 2/3), as well as Avexitide in post-bariatric hypoglycemia (Phase 3) and AMX0114, an antisense oligonucleotide for ALS (Phase 1). With the commercial product discontinued, Amylyx's near-term value hinges on clinical readouts and successful pipeline advancement, though investor sentiment remains cautious.

Upcoming Catalysts (preview)

• H2 2026Phase 3 data for Avexitide in post-bariatric hypoglycemia55% success
• H2 2026Phase 2 data for AMX0035 in Wolfram Syndrome40% success
• 2027Initial data update for AMX0114 in ALS30% success